文献速递类风湿关节炎

HIV感染中类风湿关节炎的发病、表现与治疗

Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment.
PubMed 文献 · Arthritis Rheumatol · 2021-10-28

基于退伍军人老龄化队列研究,HIV感染者类风湿关节炎发病率为未感染者的0.29倍(95%CI 0.19-0.48)。HIV合并RA患者自身抗体高滴度比例较低,且DMARDs处方率低于无HIV的RA患者,未见DMARD安全性更差的迹象。

要点

  • HIV感染者发生RA的风险显著低于未感染者(IRR 0.29,95%CI 0.19-0.48)。
  • HIV合并RA患者高滴度抗CCP和RF的比例低于无HIV的RA患者。
  • HIV合并RA患者DMARDs处方率较低,但未见安全性更差。

核心结论

  • 在本队列中,HIV感染者发生RA的风险低于未感染者。
  • HIV合并RA患者RA特异性自身抗体血清阳性率及滴度低于无HIV的RA患者,且DMARDs处方率更低。

研究设计与样本

  • 退伍军人老龄化队列研究,纵向队列,纳入HIV感染退伍军人与年龄、种族、地点匹配的未感染退伍军人。
  • 研究纳入56,250例HIV感染者与116,944例未感染者,共2,384,541人年。
  • 通过ICD-9或ICD-10代码筛选并经病历复核确认符合2010年ACR/EULAR RA分类标准,记录DMARD使用及不良反应。

主要发现

  • 在2,748例因ICD代码被复核的个体中,发现215例新发RA,其中HIV感染者21例。
  • HIV感染者相比未感染者的RA发病率比为0.29(95%CI 0.19-0.48)。
  • 88%的RA患者RA相关自身抗体(RF和/或抗CCP)血清阳性。
  • HIV合并RA患者中仅5%(1/21)同时具有高滴度抗CCP和高滴度RF,而未感染者中为41%(81/194)。
  • HIV合并RA患者中71%(15/21)使用DMARDs,而未感染RA患者中为94%(183/194)。

关键数值与推荐

  • RA诊断需满足2010年ACR/EULAR分类标准。
  • DMARDs治疗疗程定义为首次连续治疗且中断不超过6个月。
  • DMARD安全性评估基于HIV合并RA患者10例与无HIV的RA患者158例。

临床怎么用

  • 在HIV感染者中诊断RA时需注意其自身抗体高滴度比例较低,应结合临床与2010年ACR/EULAR标准综合判断。
  • HIV合并RA患者使用DMARDs的处方率较低,但本队列未提示安全性更差,治疗决策需个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the incidence, presentation, and management of rheumatoid arthritis (RA) in patients with HIV, including the use of disease-modifying antirheumatic drugs (DMARDs) in this immunosuppressed population. METHODS: Patients included in this study were from the Veterans Aging Cohort Study, a longitudinal cohort of veterans with HIV and age-, race-, and site-matched uninfected veterans. We identified all patients who had ≥1 rheumatologist-generated International Classification of Diseases, Ninth Revision (ICD-9) or Tenth Revision (ICD-10) code for RA and whose serum samples were tested for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. To further confirm the diagnosis of RA, medical charts were reviewed to verify whether patients met the American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria for RA. We recorded DMARD use and adverse effects during the first contiguous course of treatment (i.e., >6 months of no interruption in DMARD treatment). RESULTS: This study included 56,250 patients with HIV and 116,944 uninfected individuals over 2,384,541 person-years. Of the 2,748 individuals in this cohort who were reviewed for a diagnosis of RA based on ICD-9 or ICD-10 codes, incident RA was identified in 215 individuals, including 21 patients with HIV. The incidence rate ratio of RA for patients with HIV compared to uninfected individuals was 0.29 (95% confidence interval 0.19-0.48). Most of the patients diagnosed as having RA (88%) were seropositive for RA-associated autoantibodies (RF and/or anti-CCP). However, high autoantibody titers were less frequent in RA patients with HIV compared to RA patients without HIV. In total, 5% of RA patients with HIV (1 of 21) had both high titers of anti-CCP and high titers of RF, compared to 41% of uninfected individuals (81 of 194). DMARDs were prescribed in 71% of RA patients with HIV (15 of 21) compared to 94% of RA patients without HIV (183 of 194). There was no indication that the DMARD safety profile was worse among RA patients with HIV who were prescribed DMARDs (n = 10 assessed) compared to RA patients without HIV who were prescribed DMARDs (n = 158 assessed). CONCLUSION: In this cohort, incident RA was less common in patients with HIV compared to uninfected individuals. Moreover, compared to RA patients without HIV, the seropositivity rate and titers of RA-specific autoantibodies were lower among RA patients with HIV, and those with HIV were prescribed DMARDs less frequently than those without HIV.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hanberg JS, Hsieh E, Akgün KM, et al. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment. Arthritis Rheumatol. 2021. PMID: 34042306. doi:10.1002/art.41802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。